LAUSR

Oncogenic mutations in KRas are found in more than 90% of pancreatic tumors. These mutations are acquired at an early stage of disease and, in experimental models, have been shown to be essential for tumor initiation, progression and maintenance. Studies from our lab have shown that the growth of oncogenic KRas harboring pancreatic tumors is associated with an immuo-suppressed state that is established via the dynamic interplay between the tumor cells and the immune milieu. Molecular dissection of the mechanisms that mediate this interplay reveals the engagement of a transcriptional program that drives the expression of a plethora of cytokines and chemokines. This presentation will focus on a subgroup of cytokines and the role they play in activating specific immunosuppressive pathways. The implication of our findings to disease progression and therapeutic intervention will be discussed. Citation Format: Dafna Bar-Sagi. Immune rewiring of mutant Ras tumors: Mechanisms and translational implications [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr IA21.